#96214: Attention Deficit Hyperactivity Disorder

The diagnostic evaluation of a child or teenager suspected to have ADHD requires a thorough evaluation, including information from parents and teachers. Laboratory, radiologic, and other studies are not usually needed. However, in 2013, a device based on electroencephalogram (EEG) technology was approved to help assess ADHD in children and adolescents 6 to 17 years of age [12]. The Neuropsychiatric EEG-Based Assessment Aid System calculates the ratio of theta and beta waves, which are shown to be higher in children with ADHD. The role of this device has not yet been established, and it should not be used alone to diagnose ADHD.

Both the American Academy of Pediatrics (AAP) and the American Academy of Child and Adolescent Psychiatry (AACAP) have developed recommendations for the assessment of ADHD. The AAP guideline for the diagnosis of ADHD was revised in 2019, and this updated guideline is in line with DSM-5-TR criteria and provides a general guide for identifying the disorder in children 4 to 18 years of age [13]. The AACAP guideline, published in 2007, addresses ADHD in children and adolescents between 3 and 17 years of age [9].

According to the American Academy of Pediatrics, the clinician should initiate an evaluation for ADHD for any child or adolescent 4 to 17 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity

(https://pediatrics.aappublications.org/content/144/4/e20192528 Last Accessed: September 28, 2024)

Level of Evidence: B (Randomized controlled trials or diagnostic studies with minor limitations; overwhelmingly consistent evidence from observational studies)

Mental health assessment should include screening for ADHD [9]. The AACAP guideline assumes a psychiatric primary complaint, but any child may be screened for ADHD using questions about impulsivity, hyperactivity, and inattention. If ADHD is suspected, additional evaluation can be pursued.

Full evaluation should include information from both the parent and child and should incorporate information about functioning at school or day care [9,13]. Each symptom in the diagnostic criteria should be assessed and duration, frequency, and severity determined. The possibility of comorbid disorders, including learning disability and depression, should be explored. In addition to parent and patient interviews, family history and developmental history may increase the likelihood of ADHD diagnosis or shed light on comorbid disorders or other underlying causes of symptoms. A standardized behavior rating scale should be completed by a parent and, if possible, a teacher. Report cards and homework papers may also be helpful.

Unless medical history indicates, laboratory tests and neurologic testing are not needed [9]. Some medical conditions can cause behavior similar to ADHD, but other indications of an underlying cause will usually be present. Children who are likely to have had lead exposure, such as those in inner cities or older housing, may benefit from lead testing because this exposure has been associated with ADHD. Hyperthyroidism, on the other hand, does not usually present as purely ADHD with no other symptoms. Imaging, such as magnetic resonance imaging and electroencephalography, are not part of the routine evaluation of ADHD [9]. They should be reserved for cases when a specific indication is present.

Psychologic and neuropsychologic testing are also not generally needed. However, patients who appear to have low cognitive ability and those whose math or language performance does not seem to match their ability may require this type of evaluation. Testing can help differentiate learning disorders from learning problems that are secondary to ADHD.

Special attention should be paid to the possibility of a comorbid psychiatric disorder [9]. Comorbidities are common in patients with ADHD and may require additional treatment. In addition, symptoms resembling ADHD may be due to another psychiatric problem. ADHD itself may lead to some of the symptoms of depression or mania. When patients meet full criteria for ADHD plus another disorder, both diagnoses should be made.

As in children, diagnosis in adult patients should involve a careful history and diagnostic interview. The interview should cover childhood symptoms and developmental history, as well as current symptoms and impact on the patient's life [14]. Input from a close friend, parent, or spouse may be helpful, and alternative psychiatric diagnoses and comorbidities should be considered. A physical exam should be performed; testing should be pursued as needed to evaluate for potential physical causes for symptoms, such as hearing and vision problems, anemia, and hyperthyroidism. Current medications should be discussed to help rule out the possibility that symptoms are due to medication side effects.

There are several changes in symptoms as patients approach adulthood. There appear to be fewer overt symptoms of hyperactivity (e.g., running and climbing, inability to remain seated), but these may be replaced with or confined to fidgetiness, jitteriness, or restlessness. Restlessness may lead to difficulty participating in sedentary activities and even avoiding sedentary occupations. Impulsivity may manifest as a tendency to make decisions without thinking them through [19]. Patients may start on projects without reading or listening to instructions. An adult with ADHD may also have a tendency to speed when driving.

Other typical adult ADHD symptoms include having trouble getting organized, planning ahead, or preparing for events [19]. These patients may appear inefficient, failing to do tasks in the order that makes the most sense. Inattention may manifest as failure to persist in uninteresting tasks or daydreaming instead of concentrating.

Several screening tools have been developed for adults. The World Health Organization (WHO) created a short and long version of the Adult ADHD Self-Report Scale (ASRS) [20]. The ASRS has good specificity (98.3% long version and 99.5% short version) but limited sensitivity (56.3% and 68.7%). Because this version of the ASRS was calibrated to DSM-IV criteria, which are narrower than DSM-5-TR criteria, researchers sought to update the ASRS for DSM-5-TR criteria [21]. A semistructured diagnostic interview for DSM-5-TR adult ADHD was administered to two general population surveys: 119 from a household survey and 218 from a managed care subscriber survey. A novel algorithm was applied to the pooled data to create a DSM-5-TR version of the ASRS. The accuracy of the new scale was then confirmed in independent clinical samples of patients seeking evaluation at the New York University Langone Medical Center Adult ADHD Program (NYU Langone) from 2011–2012 and in 300 primary care controls from 2015–2016. Data analysis was conducted from April to September 2016. Of the 637 total participants, 44 household survey respondents, 51 managed care respondents, and 173 NYU Langone respondents met DSM-5-TR criteria for adult ADHD. Of these, 123 were male, with a mean age of 33.1 years. A six-question screening scale was found to be optimal in distinguishing ADHD from non-ADHD individuals in the first two samples. The DSM-5-TR ASRS screening scale detected most general population cases of ADHD with a high specificity and positive predictive value [21].

The Utah criteria are a set of diagnostic criteria developed specifically to identify adults with ADHD [22]. Although they do not match the DSM-5-TR definition, they may be useful in assessing adult patients. The Utah criteria include [22]:

These criteria have several limitations. Patients with the inattentive subtype of ADHD may be missed. When hyperactivity is present in childhood ADHD, it tends to decline over time or manifest in more subtle ways. The listed symptoms, particularly lability and outbursts of temper, may indicate other psychiatric disorders. Although early research suggested that "hot temper" and irritability were aspects of ADHD, it has been found that such symptoms are associated more with the social environment and that they predict different developmental outcomes [23]. Problems with temper may be associated with ADHD but are no longer considered part of the diagnostic criteria.

Barkley and colleagues have suggested diagnostic criteria based largely on patients in an adult ADHD study based at the University of Massachusetts (UMASS) Medical School [19]. This study involved comparing adults with ADHD to adults with other disorders and to a community sample (control). Patients were recruited through an adult ADHD clinic, and community controls were recruited through flyers and advertisements. When characteristics of the adults with ADHD were compared to those of the other two groups, there were clear differences. Being easily distracted by extraneous stimuli was a clear dissimilarity between adults with ADHD and community controls; in fact, this one symptom clearly divided the two groups. However, it did not necessarily separate adults with ADHD from those with other disorders. An additional set of symptoms was found to be useful in distinguishing ADHD from other psychiatric problems. Patients more likely to have ADHD were those who often [19]:

Two additional symptoms, having difficulty sustaining attention in tasks or play activities and having difficulty organizing tasks and activities, added a small increase in classification accuracy between patients with ADHD and community controls. The proposed diagnostic criteria suggest that adults who have six of these nine symptoms, in addition to meeting certain other criteria (including onset of symptoms prior to the age of 16 years), may be considered to have ADHD. Interestingly, in this study the diagnostic criterion of having trouble staying seated when expected to do so was more likely to identify a patient with some other psychiatric disorder than an adult with ADHD.

Stimulant medications, including amphetamine and methylphenidate, are considered first-line therapy in the treatment of ADHD [5,28]. However, other medications, such as atomoxetine, may be considered [5]. Behavior modification has a role in the overall treatment plan of ADHD, and cognitive-behavioral therapy (CBT) may be helpful for adults, although the evidence for stimulant medications is stronger.

Both the AACAP and AAP guidelines regarding ADHD include recommendations for the treatment of children and adolescents. There are no current guidelines for adult treatment from national organizations in the United States, but a Canadian group and the United Kingdom's National Institute for Health and Care Excellence (NICE) have published recommendations that may be helpful [29,30,31]. The NICE guideline contains recommendations for the diagnosis and management of ADHD in children, adolescents, and adults [31].

The AAP guideline emphasizes the need to view ADHD as a chronic disease and treatment as an ongoing process [13]. It recommends collaboration among the child, parents, and teachers to set goals and evaluate progress. Systematic follow-up is needed to assess the effects of treatment, whether medication, behavior therapy, or both, and to determine whether adjustments are needed. A child who fails to respond to one stimulant may respond to another. If treatment is not having a positive effect, evaluation should include adherence, the possibility of comorbid conditions, and confirmation that ADHD is the correct diagnosis.

Guidance from the 2007 AACAP guideline includes the recommendation that the treatment plan should be comprehensive but flexible and should be reviewed regularly [9]. It should include education for both the patient and his or her parents and take advantage of school and community resources and supports. Education should focus on information about ADHD, prepare parents for developmental challenges common in affected children, and provide general advice about managing behavior and academic functioning. The NICE guideline recommends that healthcare providers have regular discussions with patients with ADHD and their families or caregivers regarding their desired level of involvement in treatment planning and decisions. Ensuring continuity of care is stressed [31]. The NICE guideline also recommends that prior to starting any treatment, healthcare providers should discuss with patients and their families: the benefits/harms of treatment, both pharmacologic and nonpharmacologic; potential adverse effects and nonresponse rates; benefits of a healthy lifestyle, including exercise; their preferences and concerns; the impact of other mental health or neurodevelopmental conditions on treatment choices; and the importance of adherence to treatment [31].

For elementary and middle school-aged children (6 to 11 years of age), the American Academy of Pediatrics recommends prescription of an FDA-approved medications for ADHD, along with parent training in behavior management and/or behavioral classroom intervention (preferably both).

(https://pediatrics.aappublications.org/content/144/4/e20192528 Last Accessed: September 28, 2024)

Level of Evidence: A (Well-designed randomized controlled trials or diagnostic studies on relevant populations)

First-line medical therapy with agents that are approved by the U.S. Food and Drug Administration (FDA) for ADHD is also recommended [9]. If treatment with these agents fails, the diagnosis should be reconsidered and either changed or confirmed. Off-label medications should be used for ADHD only if all the approved agents have proven unsatisfactory [9]. Treatment with behavior therapy alone may be helpful in these cases. For children younger than 5 years of age, the NICE recommends parent or caregiver participation in an ADHD-focused group training program as first-line treatment [31]. Medication for ADHD for any child younger than 5 years of age is not recommended without a second specialist opinion [31].

Healthcare professionals should be alert for side effects of medications used in the treatment of ADHD and manage them as needed. Dose reduction or a change to a different medication may be necessary. In some cases, the medication that helps the most with ADHD will also have a bothersome side effect. If this medication must be continued, certain adjunctive medications to treat the side effect may be helpful.

If medication achieves a satisfactory response, then additional treatment such as behavioral therapy is not essential, although it may be offered. Parental preference should be considered in this case [9]. Psychosocial treatment may be helpful when the response to medication is sub-optimal, when family stressors are present, or when there is a comorbid disorder.

Periodic assessments should be conducted at least several times each year for children taking medication for ADHD. If symptoms are no longer present and this continues for at least one year, consideration may be given to stopping treatment. Treatment can be restarted if ADHD signs or symptoms return.

In general, the approach for adults is similar, with many experts agreeing that pharmacotherapy is an appropriate first-line option. Some also feel that many adults will benefit from psychosocial therapy to assist them in learning important coping skills or overcoming a demoralizing self-image.

The 2018 guideline from the Canadian ADHD Resource Alliance (CADDRA), a not-for-profit alliance of professionals working in the area of ADHD, includes a section on ADHD in adults [29]. CADDRA recommends the use of mixed amphetamine salts (extended-release), long-acting methylphenidate, or atomoxetine as first-line agents. Short- or intermediate-acting stimulants are recommended as second-line or adjunctive agents, for example if a patient requires additional medication in the evening, when a long-acting preparation wears off. The guideline also recommends psychologic interventions, such as ongoing education about ADHD and coping strategies. Patients' goals should be discussed and treatment structured accordingly.

The 2018 NICE guideline asserts that treatment for adults should be comprehensive and should address psychologic, behavioral, and occupational or educational needs [31]. The recommended first-line medication is lisdexamfetamine or methylphenidate, with atomoxetine or dexamphetamine as options if lisdexamfetamine or methylphenidate cannot be tolerated or does not produce an optimal response. Six weeks of lisdexamfetamine or methylphenidate is suggested as adequate trial [31].

Behavioral therapy is a term commonly used to describe a type of psychosocial approach to treating childhood ADHD. One aspect of this therapy is parent training; a typical program of behavioral therapy involves 10 to 20 sessions for parents, including information about ADHD and advice on managing behavior, anticipating misconduct, using a token economy, and using a daily school report card [9]. Therapies for children may include teaching skills and adaptive behaviors, such as how to organize school materials or how to improve relationships with peers [73]. Parent training in behavior therapy (also known as behavior management training for parents, parent behavior therapy, and behavioral parent training) has been shown to strengthen the relationship between the parent and child and to decrease children's negative or problem behaviors [74].

The Multimodal Treatment Study of Children with ADHD was a 14-month trial of specific medication management, intensive behavioral therapy (group and individual sessions, teacher consults, a classroom behavioral aide for 12 weeks, and a summer program), both medication and behavioral therapy, or ordinary community care [75]. This study revealed that combination treatment did not significantly differ from medication management alone on direct comparisons.

Combined treatment was found to be superior to intensive behavioral therapy and/or community care for oppositional and/or aggressive symptoms, internalizing symptoms, teacher-rated social skills, parent-child relations, and reading achievement. At follow-up three and eight years after intensive study treatments had concluded, all treatment groups were similar on measures of ADHD symptoms [76,77].

A two-year trial compared the efficacy of methylphenidate alone; methylphenidate with psychosocial treatment (including parent training and counseling, social skills training, psychotherapy, and academic assistance); and methylphenidate plus a psychosocial control treatment [78]. Significant improvement was seen with all treatments; combination treatment did not provide an advantage.

A randomized clinical trial compared combined treatment (brief intensive multimodal behavior therapy and methylphenidate) to treatment with methylphenidate alone. The 45 children who participated were reassessed at adolescence in a naturalistic follow-up 4.5 to 7.5 years after treatment. A matched non-ADHD control group included 23 children. Of the adolescents who participated in the follow-up study, 50% still met the diagnostic criteria for ADHD [79]. Adolescents in the combined treatment group used significantly less medication than those in the methylphenidate-alone group. Overall, the adolescents showed a significant decline in hyperactivity/impulsivity and oppositional and CD symptoms from post-test to follow-up. Adolescents originally diagnosed with ADHD fared significantly worse than the matched controls on all outcomes except CD and substance abuse symptoms [79].

As stated, for children younger than 5 years of age, the NICE recommends parent or caregiver participation in an ADHD-focused group training program as first-line treatment [31]. The NICE guideline also recommends training for parents and caregivers of school-aged children with ADHD [31]. Parent training and group-based ADHD-focused support is recommended for parents of school-aged children who display symptoms of oppositional defiant disorder (ODD) or CD [31]. This guideline also recommends that CBT be considered in children who have benefited from medication but whose symptoms continue to cause significant impairment in social skills with peers, problem-solving, self-control, active listening skills, and dealing with and expressing feelings [31].

Evidence regarding psychosocial treatments in adults is very limited. However, there may be a role for CBT [80,81]. A few small studies support the use of CBT programs, and CBT is often used in practice. The NICE guideline recommends either elements of or a full program of CBT for adults with ADHD in whom nonpharmacologic treatment is indicated [31].

The focus of CBT for ADHD in adults includes both the patient's thought process and his or her coping behaviors. Cognitive therapy addresses beliefs that reinforce problematic behaviors, such as feelings of failure; the goal is to diminish the power of such beliefs and to help the patient cope efficiently with the symptoms that led to them. In addition, there are many specific skills and behaviors that patients can learn, such as ways to improve organization or reduce the chance of making an impulsive decision. These skills can be individualized, depending on what works best for each patient.

Other areas of patients' lives may also be affected by ADHD. For adults, couples counseling, family therapy, and education about parenting may all be of use. Some patients will also benefit from therapy to improve their interpersonal skills.

In 2019, the FDA permitted marketing of the first medical device for the treatment of ADHD [82]. The Monarch external Trigeminal Nerve Stimulation (eTNS) System is indicated for patients 7 to 12 years of age who are not currently taking prescription ADHD medication. The device consists of a cell-phone-sized device that generates a low-level electrical pulse and connects via a wire to a small patch that adheres to a patient's forehead, just above the eyebrows [82]. TNS is done at home during sleep and may take up to four weeks to produce a noticeable response. In studies, children who used TNS showed considerable improvements in severity and frequency of ADHD symptoms [82]. The most common side effects are drowsiness, increased appetite, sleep difficulties, teeth clenching, headache, and fatigue.

Often, ADHD is confused with learning disability, but they are distinct entities. Learning disorders are classified as specific learning disorders in the DSM-5-TR, with divisions that specify disability in reading, writing, and mathematics [11]. Specific learning disorders are listed under neurodevelopmental disorders alongside ADHD, autism spectrum disorder, communication disorders, coordination disorders, and intellectual disability [83]. An estimated 31% to 45% of children have ADHD with specific learning disorders and 5% have ADHD without specific learning disorders [84,85].

For patients with ADHD and specific learning disorders, it is important to assess whether low performance may be secondary to ADHD and/or whether inattentiveness may be due to the specific learning disorders. It is appropriate to consider treating ADHD first, as this may allow better assessment of learning problems after symptoms of ADHD improve.

In addition to deficits in learning abilities, youth with ADHD, particularly those with a family history of substance use disorder, also exhibit deficits in reward processing. One study investigated reward-based learning as a function of the severity of substance abuse risk in drug-naïve youth with ADHD [86]. The youth were asked to perform a novel anticipation, conflict, and reward task. The authors measured reaction time, accuracy, and learning rates and assessed the influence of learned predictions of reward probability and stimulus congruency on reaction times. The most significant deficits in accuracy, in learning rates, and in adjusting to task difficulty were observed in high-risk youth (i.e., those with ADHD and parental substance use disorder) [86].

In patients who have ADHD and depression, clinicians must decide whether to treat depression or ADHD first or whether to begin treatment for both at once. If the patient is experiencing a mild depression, there is a possibility that the depressive symptoms are related to demoralization resulting from the multiple functional difficulties that ADHD can cause [9,87].

There is limited evidence for the use of antidepressants in combination with ADHD medications. In a double-blind trial, children with ADHD and depression or anxiety were treated with fluoxetine or placebo for eight weeks, and then atomoxetine was added for the final five weeks of the study [88]. ADHD, depressive, and anxiety symptoms were significantly reduced in both groups. Although this may seem to suggest that both fluoxetine and atomoxetine can treat depression, lack of a placebo-only arm precludes conclusions about such an effect. The combination was well-tolerated, however.

In a small trial of sustained-release bupropion in 24 children 11 to 16 years of age with comorbid depression, clinician-rated improvement was observed in 58% of participants for both depression and ADHD, 29% for depression only, and 4% for ADHD only. Both parents' and children's ratings of depression and ADHD improved, as did parents' ratings of ADHD. Teachers' ratings for ADHD did not improve in this study [89].

Children with CD or ODD are often included in trials of ADHD treatment. Fewer studies exist that specifically assess the treatment of comorbid CD/ODD and ADHD. In a four-week randomized, double-blind study of 308 children 6 to 17 years of age with ODD, 79% of whom had comorbid ADHD, treatment with mixed amphetamine salts improved ODD symptoms as measured by parent rating scales [90]. A meta-analysis of three controlled trials concluded that atomoxetine was effective for ADHD symptoms whether or not ODD was present, and that reduction in ODD symptoms was highly related to the magnitude of ADHD response [91]. In 84 children 6 to 15 years of age with and without ADHD in a five-week randomized trial, methylphenidate improved CD symptoms [92]. A prospective study of 37 children 6 to 14 years of age with ODD and ADHD found methylphenidate and atomoxetine to be effective in the treatment of ODD comorbid with ADHD of short duration [93].

Stimulant treatment for ADHD may also help with both overt and covert aggression-related behaviors, whether or not CD or ODD is present. Overt aggression involves confrontations such as assault, threats, and tantrums. Covert aggression includes lying, cheating, and stealing. A meta-analysis involving 28 studies examined the effect of stimulants on such behaviors [94]. This analysis showed statistically significant reductions in parents' and teachers' ratings of overt aggression and in overall ratings of covert aggression as well. A retrospective review was conducted for 97 children 4 to 7 years of age, diagnosed with disruptive behavior disorders, and enrolled in an intensive outpatient behavioral intervention program [95]. Child Behavior Checklist (CBCL) scores both pre- and post-intervention were compared between children who received stimulants and those who did not. While there were significant improvements in behavior outcomes pre- and post-intervention among both groups, the authors found no benefit with the use of stimulants for long-term treatment of disruptive behavior in children younger than seven years of age [95].

Clonidine may also help with aggressive behaviors, although this is not an FDA-approved indication [35]. In a randomized trial involving 67 children with ADHD and comorbid ODD or CD, clonidine added to stimulant treatment produced significantly more responders on the conduct scale of the Connors Behavior Checklist (but not on the hyperactive index) compared to placebo and a stimulant medication [96]. Clonidine was associated with transient sedation and dizziness in this study.

Additional medications have been studied in the treatment of CD or ODD in children with ADHD. In a small, three-week study involving 24 children 12 to 16 years of age, quetiapine added to a long-acting methylphenidate reduced symptoms of ADHD in children with severe aggression who did not respond to methylphenidate alone [97]. However, a Cochrane review found no evidence to support the use of quetiapine for disruptive behavior disorders in children and adolescents, but it did find limited evidence of efficacy of risperidone in reducing aggression and conduct problems in the short term in this population [98].

A common concern clinicians and parents have when considering stimulant medications for the treatment of ADHD is the risk of substance abuse. In patients with a history of substance use disorder, amphetamines are generally contraindicated, and caution is advised with methylphenidate.

Evidence is mixed regarding whether stimulant treatment increases the risk of substance abuse, and while predictors of risk remain understudied, the presence of CD appears to predict future substance abuse [99,100,101,102,103]. Of the core ADHD symptoms, hyperactivity/impulsivity is more consistently associated with substance abuse than inattention, which is associated only with alcohol use [102]. Studies have suggested that the use of stimulant medication may protect against future substance abuse. In a 10-year follow-up study involving 140 White male children (112 reassessed at the 10-year point) who were 6 to 17 years of age at entry, there were no statistically significant associations between treatment with stimulants and drug, alcohol, or nicotine use disorders at a mean age of 22 years [100]. These results were adjusted for CD. In a five-year follow-up study comparing 94 adolescents who had been treated with stimulants to 20 who had not, no increase in the risk of substance use disorders or cigarette smoking was seen [104]. Stimulant treatment had a protective effect on development of substance use disorders and cigarette smoking, an effect that remained after controlling for CD. However, independent of treatment with stimulants, ADHD is a significant risk factor for the development of substance use disorder and cigarette smoking in both men/boys and women/girls. A 10-year follow-up study of 268 children and adolescents with and without ADHD were followed prospectively and blindly into their young adult years. Over the follow-up period, ADHD was found to be a significant predictor of any substance use disorder and cigarette smoking. Comorbid CD and ODD at baseline were also significant predictors of substance use disorder in both sexes [103].

Increasing age at initiation of treatment with stimulant medication was positively associated with the incidence of non-alcohol substance abuse disorder in one study [105]. Post hoc analysis showed that controlling for the development of antisocial personality disorder eliminated this association. A long-term follow-up study also found an association between older age at initiation of stimulant treatment and increased risk of later substance use disorder and alcohol abuse [106]. The study of 208 boys and girls with ADHD found the relative risk for substance use disorder and alcohol abuse in adulthood was 7.7 and 5.2, respectively, compared to age-matched population controls. Female sex and childhood CD were also positively associated with an increased risk of later substance and alcohol abuse [106].

Meta-analysis was conducted on six long-term studies, with a total of 674 medicated subjects and 360 unmedicated subjects [107]. Two studies had follow-up in adolescence and four in young adulthood. Subjects were followed for a minimum of four years. Compared to subjects who were not using pharmacotherapy, those who did receive medication had a 1.9-fold lower risk for substance abuse disorders. The protective effect was larger in studies that stopped at adolescence than in studies that went into adulthood. Since this review, results from multiple longitudinal studies have not found protective effects of stimulant treatment on substance use outcomes [100,105,108]. A meta-analysis of 15 longitudinal studies examined whether treatment with stimulants for ADHD predicted later substance outcomes. A total of 2,565 individuals were analyzed across five types of substance (i.e., alcohol, cocaine, marijuana, nicotine, and nonspecific drugs) for lifetime use and abuse or dependence [109]. The results indicated that substance use/abuse outcomes for children with ADHD who were treated with stimulant medication were comparable to outcomes for children with ADHD who were not treated with stimulant medication [109].

The possibility of diversion of ADHD medication, including patients sharing stimulants with friends or selling their medication, is also a concern. Experts often suggest choosing certain preparations, including the longer-acting stimulants, to help reduce the risk of both diversion and abuse.

Anxiety is comorbid with ADHD in 33% of cases, an association that aggravates inattention and concentration problems [87]. Stimulant medication has been investigated in the treatment of children with ADHD and symptoms of anxiety. One study involving 45 children 8 to 14 years of age with ADHD investigated changes in depression, anxiety, obsessive-compulsive symptoms, and health-related quality of life during treatment with methylphenidate [110]. Based on self, parent, and teacher report at baseline and at the end of the first and third months of treatment, the children were evaluated for changes in inattention, hyperactivity, impulsivity, depression, anxiety, obsessive-compulsive symptoms, and quality of life. Over three months of treatment with methylphenidate, symptoms of depression, anxiety, and checking compulsion decreased while quality of life and symptoms of inattention, hyperactivity, and impulsivity improved [110]. In a double-blind placebo-controlled study involving 176 children 8 to 17 years of age, atomoxetine was found to reduce ADHD symptoms in children with comorbid anxiety [111]. Atomoxetine was also found to reduce anxiety, on both clinician- and self-rated measures.

One small study assessed the use of fluvoxamine for anxiety in combination with methylphenidate. Twenty-six children whose ADHD symptoms had responded to methylphenidate but who still had anxiety were randomized to receive fluvoxamine or placebo in addition to the stimulant [112]. While the combination was well-tolerated, fluvoxamine was not found to have a statistically significant effect on anxiety in this group.

The role of behavior therapy in the treatment of anxiety in children also diagnosed with ADHD was examined through analysis of data from the Multimodal Treatment Study [113]. Children with ADHD plus anxiety disorders (but not ODD/CD) were likely to respond equally well to behavioral and medication treatments. Children with ADHD and no comorbidities or ADHD with ODD/CD (but without anxiety disorders) responded best to medication with or without behavioral treatments. Children with ADHD, anxiety, and ODD/CD had optimal response when treatments were combined.

The application of CBT in children with ADHD and co-occurring anxiety disorder varies depending on the type of disorder (i.e., generalized, social, or separation anxiety disorder) and should emphasize cognitive restructuring processes. Children with ADHD and anxiety disorder generally benefit less from CBT than children who are solely anxious. The distractibility and hyperactivity of the child with ADHD may interfere with and decrease the effectiveness of CBT [114].

One concern with using stimulant medications is the risk of triggering mania in a patient with bipolar disorder. Evidence is limited and based on small trials but supports stimulant use after mood is stabilized [115,116,117]. Also, the development of tics is a potential side effect of stimulant medications [87]. In general, however, treatment of ADHD with stimulants does not appear to increase existing tics and may even provide improvement [9,118,119,120,121].

Studies in teens and young adults show that diversion and misuse of stimulants are common [122,123]. One study, examining more than 100 four-year colleges in the United States, found that non-medical stimulant use was as high as 25% at some schools [124]. Data from the 2019 National Survey on Drug Use and Health indicate that the highest rates of past-year prescription stimulant misuse occurred among young adults 18 to 25 years of age (5.8%) and adolescents 12 to 17 years of age (1.7%) [125]. First use of stimulants in adolescence and adulthood may be associated with higher risk of stimulant misuse/abuse [126].

As with children, it is recommended that stimulants be used with caution if a patient has a history of substance abuse. In fact, amphetamine-based drugs are generally contraindicated in this population. If a patient has a current substance abuse problem, it is important to treat this appropriately while addressing symptoms of ADHD. When both disorders are diagnosed at once, it is often recommended that the substance use be addressed first, in part because behaviors related to substance abuse can mimic ADHD symptoms [29,127]. After the patient has stopped the substance misuse and is in recovery, he or she can be reassessed for ADHD and treated, as necessary. Evidence suggests stimulant medications may not exacerbate addiction. In a 12-week, double-blind, placebo-controlled trial involving 48 cocaine-dependent adults with ADHD, the use of methylphenidate did not lead to group differences in self-reported cocaine use or cocaine craving or in urinalysis results [128].

A double-blind, 12-week trial involving 98 methadone-maintained patients (53% of whom also had cocaine dependence/abuse) did not find evidence of medication misuse or worsening of cocaine use in a group receiving methylphenidate [129]. In this study, the reduction in ADHD symptoms was similar with methylphenidate, bupropion, and placebo, and neither treatment nor placebo appeared to offer an advantage for reducing cocaine use. In a later study with cocaine abusers, analysis of urine toxicology data suggested that methylphenidate users had less cocaine use than a placebo group during the trial [130]. A Cochrane review found that psychostimulants, including methylphenidate, appeared to increase the proportion of patients achieving sustained cocaine and heroin abstinence among methadone-maintained, dual heroin-cocaine addicts. However, retention to treatment was low [131].

There may be an advantage to using long-acting or controlled-release formulations of stimulant medications. Spencer and colleagues studied plasma d-methylphenidate levels, responses to detection/likeability questionnaires, and dopamine transporter receptor occupancies in 12 healthy adults randomly assigned to single doses of immediate-release or osmotic-release methylphenidate [132]. Subjects receiving osmotic-release methylphenidate had a longer time to maximum concentration and to maximum central nervous system dopamine transporter occupancy, and they had no detection or likeability on questionnaires. Kollins and colleagues found stimulant-like drug effects (such as increased ratings of "good effects") with immediate-release methylphenidate, while a sustained-release formulation had smaller and more transient effects [133].

There may also be an advantage in using the pro-drug lisdexamfetamine dimesylate, which was designed to limit abuse potential. Jasinski and colleagues studied "liking effects" in single IV doses of lisdexamfetamine dimesylate (25 or 50 mg) and immediate-release d-amphetamine sulfate (10 or 20 mg) compared to placebo [134]. Data was gathered in a randomized, double-blind, crossover study including 12 total subjects, all adult substance abusers. Abuse-related liking scores were higher with 20 mg of d-amphetamine than with placebo. For 50 mg lisdexamfetamine dimesylate, there was no significant difference from placebo.

Evidence is lacking to guide treatment of depression in adults who have ADHD, although selective serotonin reuptake inhibitors (SSRIs) and bupropion are common choices. Monoamine oxidase inhibitors (MAOIs) are contraindicated in patients taking stimulants or atomoxetine. With atomoxetine, caution with SSRIs that are strong cytochrome P450 2D6 (CYP2D6) inhibitors is advised as they may increase atomoxetine levels; bupropion also inhibits this enzyme [135]. With methylphenidate, caution is advised with SSRIs and tricyclic antidepressants due to the possibility of decreased metabolism of these drugs [35]. Amphetamines may enhance the activity of tricyclic antidepressants, and cardiovascular risks may be increased with this combination [136]. Caution is also advised with amphetamines in patients taking bupropion, as this is associated with an increased risk of seizures. It is also recommended that amphetamines be avoided in patients taking venlafaxine, as this combination is associated with increased weight loss [35].

Caution is advised in prescribing stimulants or atomoxetine in adults with cardiovascular concerns. A full medical history, physical exam, and additional evaluation may be needed. Sudden death, stroke, and myocardial infarction have been reported at usual doses for ADHD, but the role of the medications in these events is not known [35]. In general, it is recommended that stimulants be avoided in adults with serious cardiac structural abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious cardiac problems. Regular monitoring for changes in blood pressure and heart rate is suggested, and stimulants and atomoxetine should be used with caution if a patient has conditions that could be worsened by such changes [35]. Clinicians must be vigilant regarding cardiac symptoms that develop during treatment.

Stimulants may increase blood pressure and heart rate, but there have been few studies on the effects on this phenomenon. In an open-label trial, 13 adults with ADHD and controlled essential hypertension took extended-release mixed amphetamine salts for six weeks and then discontinued medication for two weeks [137]. The stimulant did not cause sustained blood pressure elevations, did not increase the number of single episodes of hypertension, and did not lead to a group mean increase in blood pressure or pulse.

Weisler and colleagues found that with extended-release mixed amphetamine salts used for up to 24 months, doses of 20–60 mg/day were associated with small but statistically significant changes in blood pressure and pulse [138]. At 24 months, there was a clinically insignificant increase in QT, although no subject had a QT interval greater than 480 msec. Seven subjects stopped treatment due to a cardiovascular adverse event (two for palpitations/tachycardia and five for hypertension), although none were considered serious.

Data were reanalyzed from placebo-controlled studies of five different ADHD medications (methylphenidate, amphetamine compounds, pemoline, bupropion, and desipramine) in order to evaluate the effects of these medications on blood pressure and pulse [139]. Statistically significant increases in systolic blood pressure were observed with bupropion (5.9 mm Hg) and amphetamine (5.4 mm Hg). Significant increases in diastolic blood pressure were observed with desipramine (7.1 mm Hg). Statistically significant increases in heart rate were observed for bupropion, amphetamine, and methylphenidate. The authors concluded that, in general, adults being treated for ADHD should have blood pressure and heart rate monitored during treatment.

As a result of the evolving racial and immigration demographics in the United States, interaction with patients for whom English is not a native language is inevitable. Because patient education is such an important aspect of the care of patients with ADHD, it is each practitioner's responsibility to ensure that information and instructions are explained in such a way that allows for patient or caregiver understanding. When there is an obvious disconnect in the communication process between the practitioner and patient due to the patient's lack of proficiency in the English language, an interpreter is required. (In many cases, the terms "interpreting" and "translating" are used interchangeably, but interpreting is specifically associated with oral communication while translating refers to written text.) Frequently, this may be easier said than done, as there may be institutional and/or patient barriers.

Depending upon the patient's language, an interpreter may be difficult to locate. Or, an organization may not have the funds to bring in an interpreter. Also, bringing in an interpreter creates a triangular relationship with a host of communication dynamics that must be negotiated [140]. Many view interpreters merely as neutral individuals who communicate information back and forth. However, another perspective is that the interpreter is an active agent, negotiating between two cultures and assisting in promoting culturally competent communication and practice [141,142]. In this more active role, the interpreter's behavior is also influenced by a host of cultural variables such as gender, class, religion, educational differences, and power/authority perceptions of the patient [141,142]. Consequently, an intricate, triangular relationship develops between all three parties. Another factor affecting the communication process is the fact that many interpreters are not adequately trained in the art of interpretation in mental health and general health settings, as there are many technical and unfamiliar terms. An ideal interpreter goes beyond being merely proficient in the needed language/dialect [143]. Interpreters who are professionally trained have covered aspects of ethics, impartiality, accuracy, and completeness [144]. They are also well-versed in interpreting both the overt and latent content of information without changing any meanings and without interjecting their own biases and opinions [144]. Furthermore, knowledge about cross-cultural communication and all the subtle nuances of the dynamics of communicating in a mental health or general health setting is vital [142,143].

On the patients' side, they may be wary about utilizing interpreters for a host of reasons. They may find it difficult to express themselves through an interpreter [145]. If an interpreter is from the same community as the patient, the client/patient may have concerns about sharing private information with an individual who is known in the community and the extent to which the information disclosed would remain confidential. In some cases, raising the issue of obtaining an interpreter causes the client/patient to feel insulted that their language proficiency has been questioned. Finally, if an interpreter is from a conflicting ethnic group, the patient may refuse having interpreter services [140]. The ideal situation is to have a well-trained interpreter who is familiar with health and mental health concepts.

If an interpreter is required, the practitioner must acknowledge that an interpreter is more than a body serving as a vehicle to transmit information verbatim from one party to another [145]. Instead, the interpreter should be regarded as part of a collaborative team, bringing to the table a specific set of skills and expertise [145]. Several important guidelines should be adhered to in order to foster a beneficial working relationship and a positive atmosphere.

A briefing time between the practitioner and interpreter held prior to the meeting with the client/patient is crucial. The interpreter should understand the goal of the session, issues that will be discussed, specific terminology that may be used to allow for advance preparation, preferred translation formats, and sensitive topics that might arise [143,145,146]. It is important for the client/patient, interpreter, and practitioner to be seated in such a way that the practitioner can see both the interpreter and client/patient. Some experts recommend that the interpreter sit next to the client/patient, both parties facing the practitioner [144].

The practitioner should always address the client/patient directly. For example, the practitioner should query the client/patient, "How do you feel?" versus asking the interpreter, "How does she feel?" [144]. The practitioner should also always refer to the client/patient as "Mr./Mrs. D" rather than "he" or "she" [145]. This avoids objectifying the client/patient.

At the start of the session, the practitioner should clearly identify his/her role and the interpreter's role [145]. This will prevent the client/patient from developing a primary relationship or alliance with the interpreter, turning to the interpreter as the one who sets the intervention [143]. The practitioner should also be attuned to the age, gender, class, and/or ethnic differences between the client/patient and the interpreter [145]. For example, if the client/patient is an older Asian male immigrant and the interpreter is a young, Asian female, the practitioner must be sensitive to whether the client/patient is uncomfortable given the fact he may be more accustomed to patriarchal authority structures. At the conclusion of the session, it is advisable to have a debriefing time between the practitioner and the interpreter to review the session [143,145,146].

In this multicultural landscape, interpreters are a valuable resource to help bridge the communication and cultural gap between clients/patients and practitioners. Interpreters are more than passive agents who translate and transmit information back and forth from party to party. When they are enlisted and treated as part of the interdisciplinary clinical team, they serve as cultural brokers, who ultimately enhance the clinical encounter. In any case in which information regarding diagnostic procedures, treatment options and medication/treatment measures are being provided, the use of an interpreter should be considered.